肿瘤突变负荷作为免疫治疗生物标志物的前景与挑战:IASLC病理委员会视角
IASLC病理委员会综述指出,TMB作为NSCLC免疫检查点抑制剂疗效预测标志物,多项试验显示高TMB与缓解率及无进展生存相关,但存在最佳适用疗法、预测切点、测序panel设计及跨实验室技术规范等挑战,需与其他标志物整合。
要点
- 高TMB与ICI缓解率及PFS相关,但TMB单独仅为复杂免疫互作的简化替代指标。
- TMB临床落地需明确最佳适用疗法、稳健预测切点、可接受panel及技术规范。
- 有效预测ICI疗效可能需将TMB与驱动基因、肿瘤免疫微环境等标志物整合。
核心结论
- TMB作为ICI疗效预测标志物有前景,但尚存多项挑战,需整合其他标志物才能有效预测。
研究设计与样本
- 国际肺癌研究协会病理委员会视角综述,汇总TMB作为生物标志物的临床证据、测序技术考量及实践挑战。
主要发现
- 大量临床试验和回顾性分析采用肿瘤或血液测序评估TMB,许多显示高TMB与ICI缓解率及无进展生存相关。
关键数值与推荐
- TMB为新一代测序衍生的体细胞突变数量,理论上越高越可能产生肿瘤新抗原。
- PD-L1免疫组化广泛用于NSCLC中PD-1抑制剂选择,但预测缓解的敏感性和特异性不够稳健。
临床怎么用
- 目前TMB不宜单独用于常规临床选择ICI患者,需结合PD-L1、驱动基因及免疫微环境等综合评估。
局限性
- TMB最佳预测切点尚未稳健定义,可接受的测序panel大小和设计未确定。
- 不同实验室间需可靠技术与信息学规范以生成精确准确的TMB测量。
- 尚需明确哪些疗法的疗效最适合由TMB状态来指导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients with NSCLC and have led to unprecedented improvements in response rates and survival in a subset of patients with this fatal disease. However, the available therapies work only for a minority of patients, are associated with substantial societal cost, and may lead to considerable immune-related adverse events. Therefore, patient selection must be optimized through the use of relevant biomarkers. Programmed death-ligand 1 protein expression by immunohistochemistry is widely used today for the selection of programmed cell death protein 1 inhibitor therapy in patients with NSCLC; however, this approach lacks robust sensitivity and specificity for predicting response. Tumor mutation burden (TMB), or the number of somatic mutations derived from next-generation sequencing techniques, has been widely explored as an alternative or complementary biomarker for response to ICIs. In theory, a higher TMB increases the probability of tumor neoantigen production and therefore, the likelihood of immune recognition and tumor cell killing. Although TMB alone is a simplistic surrogate of this complex interplay, it is a quantitative variable that can be relatively readily measured using currently available sequencing techniques. A large number of clinical trials and retrospective analyses, employing both tumor and blood-based sequencing tools, have evaluated the performance of TMB as a predictive biomarker, and in many cases reveal a correlation between high TMB and ICI response rates and progression-free survival. Many challenges remain before the implementation of TMB as a biomarker in clinical practice. These include the following: (1) identification of therapies whose response is best informed by TMB status; (2) robust definition of a predictive TMB cut point; (3) acceptable sequencing panel size and design; and (4) the need for robust technical and informatic rigor to generate precise and accurate TMB measurements across different laboratories. Finally, effective prediction of response to ICI therapy will likely require integration of TMB with a host of other potential biomarkers, including tumor genomic driver alterations, tumor-immune milieu, and other features of the host immune system. This perspective piece will review the current clinical evidence for TMB as a biomarker and address the technical sequencing considerations and ongoing challenges in the use of TMB in routine practice.
引用
- Sholl LM, Hirsch FR, Hwang D, et al. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2020. PMID: 32522712. doi:10.1016/j.jtho.2020.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。